Celldex Therapeutics shares surge as lead asset shows promise in skin conditions

Australia News News

Celldex Therapeutics shares surge as lead asset shows promise in skin conditions
Australia Latest News,Australia Headlines
  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 53 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 24%
  • Publisher: 97%

Experimental treatment proves effective in treating hives and an inflammatory skin disease

Celldex Therapeutics CLDX, +8.20% shares jumped more than 30% premarket on Monday after the company released positive clinical trial results for its lead asset in both chronic hives and an inflammatory skin disease.

The treatment, a monoclonal antibody called barzolvolimab, produced clinically meaningful responses in patients with moderate to severe chronic spontaneous urticaria, which is characterized by hives that last six weeks or longer and have no identifiable causes, Celldex said in a release Monday. Data from more than 200 patients showed that barzolvolimab achieved the study’s primary goal, which was a statistically significant change in hives activity after 12 weeks, compared with a placebo, the biotech company said.

Separately, Celldex on Sunday released promising early-stage results from a trial of barzolvolimab in prurigo nodularis, a chronic skin disorder that causes an itchy rash. Celldex is looking to start a phase 2 study of the treatment in prurigo nodularis early next year, president and CEO Anthony Marucci said in a statement.

The early efficacy data are “highly encouraging” and support the thesis that the treatment could be a best-in-class therapy, Leerink Partners analysts said in a note Sunday.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

MarketWatch /  🏆 3. in US

Australia Latest News, Australia Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Cargo Therapeutics to offer 18.8 million shares in IPO priced at $15 to $17 eachCargo Therapeutics to offer 18.8 million shares in IPO priced at $15 to $17 eachCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Read more »

Treat Your Parched Skin To These 39 Hydrating ProductsTreat Your Parched Skin To These 39 Hydrating ProductsThese things will give your skin that 'ahhh, refreshing' feel.
Read more »

The Watchdog Nation Electricity Club is where Texans share electricity woes and winsThe Watchdog Nation Electricity Club is where Texans share electricity woes and winsFrom solar power to PowerToChoose.org, Texans have strong ideas about their electricity service
Read more »

Hudson County communities share nearly $9 million in state aid for road improvementsHudson County communities share nearly $9 million in state aid for road improvementsMore than 40% of the funding, $66.7 million, is going to 173 municipalities with Complete Streets policies.
Read more »

‘I pray with them’: Pro-Palestinian college activists share message for families of kidnapped Israelis‘I pray with them’: Pro-Palestinian college activists share message for families of kidnapped IsraelisAmerican University students that participated in a walkout event in support of Palestinians in Gaza and the West Bank said they sympathize with the families of Israeli hostages.
Read more »



Render Time: 2025-02-26 17:32:30